Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination With Investigational (DTaP-IPV-Hep B-PRP~T) or Infanrix Hexa Vaccines in Latin America [EXTENSION OF PROFILES 700058507 AND 700229466]
Latest Information Update: 01 May 2016
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Pneumococcal 7-valent CRM197 vaccine conjugate; RIX 4414
- Indications Diphtheria; Haemophilus meningitis; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 04 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 22 Nov 2013 New trial record